Next-Generation DNA Synthesis (NGDS)
Sustainable, Enzymatic DNA Synthesis Platform

Transform Your Research. Protect Our Planet.

The Environmental Challenge of Chemical DNA Synthesis

Traditional chemical DNA synthesis, though foundational for genomics and biotechnology, presents serious challenges for modern laboratories and responsible innovation:

Toxic Chemistry & Hazardous Waste

Chemical methods rely on dangerous solvents like acetonitrile and dichloromethane, plus strong acids and oxidizers in every cycle. This creates hazardous waste, increases lab risks, and demands costly disposal procedures.

High Carbon Emissions

Energy-intensive processes for solvent production, transportation, and waste handling add significantly to your carbon footprint.

ESG Compliance Barriers:

Such practices make it difficult for organizations to meet growing Environmental, Social, and Governance (ESG) standards—posing operational, reputational, and regulatory challenges.

Efficiency Limitations

Chemical synthesis struggles with longer DNA constructs due to compounding errors and lower yields, constraining cutting-edge genomics and synthetic biology applications.

NGDS: The Eco-Friendly Revolution in DNA Synthesis

YD Biolabs’ proprietary Next-Generation DNA Synthesis (NGDS) platform is a breakthrough solution—delivering high-fidelity, on-demand DNA synthesis while dramatically minimizing environmental impact. NGDS empowers labs to create precise oligonucleotides in-house, revolutionizing science sustainably.

NGDS Cycle – Enzymatic DNA Synthesis Workflow
Our NGDS platform employs a highly efficient, two-step enzyme-driven cycle to achieve precise sequence-specific synthesis of oligonucleotides:

Step 1: Targeted Nucleotide Addition (N+1)
A specialized NGDS enzyme adds a single, 3’-blocked nucleotide (A, T, C, or G) to a solid-supported initiator strand (ssDNA). This controlled nucleotide-addition ensures exceptional accuracy, building the DNA sequence one base (nucleotide) at a time.

Step 2: Controlled Deblocking and Preparation for Next Synthesis Cycle
The 3’-blocking group of incorporated nucleotide is carefully and gently removed through minimal, aqueous wash steps. This deblocking fully restores the integrity of the growing DNA strand, preparing it for the subsequent nucleotide addition.

By repeating this precise cycle, our technology reliably produces oligonucleotides of any desired sequence and length with superior fidelity and efficiency.

Benefits of NGDS

🌱 Environmental Excellence 🌱
  • Zero Toxic Solvents: Water-based, enzymatic reactions—no more hazardous organic solvents.
  • Minimal Carbon Footprint: Low energy usage and reduced reagent transport emissions.
  • Waste-Free: Almost no toxic waste; lab safety and cleanup are dramatically improved.
  • Supports ESG Goals: Demonstrates real action toward corporate sustainability and compliance.
🧪Operational and Scientific Advantages🧪
  • On-Demand, In-Lab Synthesis: No reliance on external providers; gain full project control.
  • Accurate, High-Fidelity Results: Enzymatic precision for trustworthy, reproducible science.
  • Simple Workflow: Minimal handling, fast iterations, and easy integration into research pipelines.

NGDS vs. Chemical Synthesis: ESG and Environmental Impact

Aspect

NGDS (Enzymatic)

Chemical Synthesis

Environmental Impact

Water-based, eco-friendly, near-zero wastes

Heavy toxic waste; hazardous solvents

Carbon Emissions

Very low, minimal energy use

High; energy-intensive throughout

Safety

Safe for personnel, non-toxic reagents

Risky: hazardous chemicals & vapors

ESG Alignment

Strong: advances sustainability, compliance

Weak: complex mitigation, high liability

Turnaround and Workflow

Immediate, in-house, scalable

Outsourced, potential supply delays

Application of NGDS

Custom Oligo Synthesis

For gene assembly, barcoding, probe, and aptamer development.

CRISPR Guide RNA Design

Sustainable synthesis for rapid, accurate CRISPR workflows.

Synthetic Biology

Build complex biological circuits with high accuracy and low impact.

High-Throughput Sequencing

Barcodes and libraries for NGS, with minimal waste.

Ready to join the future of science—without compromise?

YD Biolabs – Where Enzymes Meet Nucleic Acids, and Science Meets Sustainability.

ATHENA - Automated DNA Labeling System

Transforming DNA labeling from complex protocols into simple breakthroughs

The Challenge: Current DNA Labeling Methods Fall Short

DNA end labeling and modification are fundamental techniques in molecular biology, yet both chemical and enzymatic labeling approaches face significant limitations that constrain research and production capabilities. Current methods present multiple challenges that impact efficiency, yield, purity, and safety in laboratory workflows.

Hazardous reagents:

Traditional DNA labeling methods often use toxic chemicals or radioisotopes, posing safety risks in the lab.

Inconsistent enzymatic labeling

Manual oligonucleotide labeling workflows can introduce variability, especially in micro-volume or multi-step reactions.

Incomplete labeling & low purity

Some methods fail to fully label DNA ends, reducing the efficiency of downstream applications.

Substrate compatibility issues

Not all enzymes work on every DNA end type, requiring multiple tailored steps.

Limited sequence compatibility

Structured DNA or secondary structures may block enzymatic labeling.

High cost & low scalability

Chemical handling, extensive purification, and manual workflows increase time and expense, limiting high-throughput capacity.

The Solution: ATHENA – Automated DNA Labeling System

YD Biolabs’ ATHENA platform is a fully automated DNA labeling system designed to overcome the limitations of traditional chemical and manual methods. By leveraging enzymatic DNA labeling, ATHENA enables high-quality, reproducible oligonucleotide labeling directly in the lab, reducing variability, turnaround time, and safety risks associated with conventional workflows.

The ATHENA platform supports scalable oligonucleotide labeling workflows and in-house DNA labeling services, allowing researchers and organizations to generate high-purity labeled oligos efficiently for applications ranging from basic research and diagnostics to large-scale production.

Empowering Scientific Discovery

ATHENA transforms DNA labeling from a manual, error-prone process into a robust, high-throughput, and reproducible workflow. By addressing the challenges of traditional DNA modification, ATHENA ensures consistent results, precise labeling, and enhanced laboratory efficiency, empowering modern research and production pipelines.

 
Advantages of ATHENA – Automated DNA Labeling System
Environmentally friendly processes

Aqueous reactions replace toxic organic solvents.

Higher purity labeled oligos

Reduced chemical damage and fewer side products.

Improved scalability

Efficient for both research-scale and large-scale production.

Consistent enzymatic labeling

Minimized run-to-run variation compared to chemical methods.

Applications of ATHENA – Automated DNA Labeling System
Probe Preparation
  • dPCR and qPCR probes for quantitative analysis and detection
  • FISH probes for fluorescence in situ hybridization studies 
  • Microarray probes for high-throughput genomic analysis 
Therapeutic Development
  • Oligo-drug conjugation for targeted therapeutic delivery 
  • Oligo-peptide conjugation for enhanced bioactivity and specificity
  • Gene therapy applications utilizing modified oligonucleotides
Research and Diagnostics
  • DNA immobilization for biosensor platforms and diagnostic devices
  • Mixed oligonucleotide pool labeling for gene-target catcher applications
  • NGS sequencing preparation and molecular diagnostics

YD Biolabs – Where Enzymes Meet Nucleic Acids, and Science Meets Sustainability.

Antibody-Oligonucleotide Conjugate (AOC) Platform

Precision Conjugation for Advanced Therapeutics and Diagnostics

YD Biolabs’ Antibody-Oligonucleotide Conjugate (AOC) platform is a next-generation technology that uses oligonucleotides as modular linkers to connect multiple payloads to antibodies. By leveraging proprietary enzymatic oligonucleotide modification and conjugation technologies, the platform enables precise, site-specific attachment of diverse payloads while maintaining high drug-to-antibody ratios (DAR) and reproducible quality for research, diagnostics, and therapeutic applications.

YD Biolabs’ Antibody-Oligonucleotide Conjugation vs. Traditional AOC Platforms
Feature YD Biolabs AOC Platform Conventional Chemical Conjugation DSS/SMCC Crosslinker Platforms
Conjugation Precision Enzyme-driven, site-specific, highly uniform Random, broad, variable Variable, lysine/cysteine-targeted
DAR/OAR Control Tunable & high, tightly controlled Heterogeneous, inconsistent Low to moderate, less controlled
Linker Chemistry Hydrophilic, DNA-based, low aggregation Often hydrophobic, increases aggregation Often hydrophobic, possible side reactions
Payload Flexibility Multi-payload, wide oligonucleotide variety Chemistry-limited, often single payload Typically single, limited
Production Scalability Highly scalable Labor-intensive, multi-step Moderate, antibody-dependent
Aggregation/Immunotoxicity Minimal (hydrophilic linker) Elevated aggregation risk Moderate to high risk
Application Breadth Broad: therapeutics & diagnostics Diagnostics, some therapeutics Diagnostics, some therapeutics
Features of Antibody-Oligonucleotide Conjugate (AOC) Platform
Oligonucleotide as a Hydrophilic Linker

Reduces aggregation and immunotoxicity of hydrophobic payloads.

Aqueous, Enzyme-Driven Reactions

Water-based, enzymatic conjugation preserves antibody activity and avoids toxic solvents.

Modular Linker Design

Enables flexible assembly of multiple payloads, accelerating ADC development.

Flexible and Scalable

Customizable linker composition and precise DAR control for reproducible, high-quality conjugates.

Advantages of Antibody-Oligonucleotide Conjugate (AOC) Platform
 🎯
Targeted Precision

Enables site-specific, multi-payload conjugation, ensuring high uniformity between batches.

💧
Enhanced Stability

Hydrophilic linkers improve solubility and prevent aggregation.

🧩
Exceptional Adaptability

Compatible with diverse antibodies and a variety of functional oligonucleotides.

📈
Manufacturing Scalability

Streamlined, enzyme-based process supports easy transition from R&D to GMP-scale production.

Applications of Antibody-Oligonucleotide Conjugate (AOC) Platform
Spatial Transcriptomics & In Situ Sequencing

High-resolution tissue profiling.

Multiplex Immunoassays & Spatial Proteomics

DNA barcodes enable high-throughput detection.

Therapeutic ADCs

Nucleic acid payloads for precision drug delivery.

Next-Generation Immuno-PCR & Hybrid ELISA

Enhanced assay sensitivity and specificity.

Targeted Nucleic Acid Delivery

Efficient platforms for RNA/DNA-based therapeutics.

Single-Cell Multiomics

Oligo-tagged antibodies for integrated profiling.

YD BioLabs – Where Antibodies Meet Nucleic Acids
Driving breakthroughs in next-generation diagnostics, therapeutics, and multiomics solutions.